Miki M, et al. - Researchers investigated novel biomarkers for recurrence prediction in pancreatic neuroendocrine tumors (PNETs). From localized G1/G2 PNETs resected curatively, samples of frozen primary tumors were used to isolate RNA and ultimately perform RNA sequencing. Using immunostaining, they assessed the expression levels of candidate genes as recurrence predictors. Patients with positive expression of C-type lectin domain family 3 member A (CLEC3A), matrix metalloproteinase-7 (MMP7), and lipocalin2 (LCN2) had significantly higher recurrence rate vs those with negative expression. For predicting the postoperative recurrence of PNETs, CLEC3A, MMP7, and LCN2 were identified as potential novel biomarkers; these are known to be related to the phosphatidylinositol-3-kinase/Akt pathway.